Saudi Arabia Dialysis Market Expands Rapidly Amid Rising CKD Prevalence and Healthcare Reforms

According to Next Move Strategy Consulting, the Saudi Arabia Dialysis Market is experiencing robust growth driven by an increasing incidence of chronic kidney disease (CKD), advancements in healthcare infrastructure, and strategic government initiatives under Vision 2030. The market is expected to reach USD 0.19 billion by 2030, with a CAGR of 4.4% by 2030.

With the prevalence of end-stage renal disease (ESRD) rising, the demand for comprehensive dialysis services—encompassing both in-center hemodialysis and home-based peritoneal dialysis—is escalating. This expansion is being supported by public-private collaborations, reimbursement reforms, and technological innovation.

Unlock FREE Sample – Try Before you Buy!

Surge in CKD Prevalence and ESRD Incidence

CKD is a mounting public health challenge in Saudi Arabia, with diabetes and hypertension—both widespread conditions—among the leading causes. Recent epidemiological data suggest that about 15% of the adult population suffers from some form of CKD, with over 30,000 patients currently receiving dialysis or living with kidney transplants. ESRD cases are estimated to rise at above 6% annually.

The demographic shift toward an aging population, combined with rising obesity and lifestyle-associated diseases, is driving demand for renal care services. Patients are seeking lifelong treatment solutions, leading the government and providers to expand dialysis offerings beyond metropolitan centers.

Hemodialysis Remains Central; Peritoneal Dialysis Adoption Rising

In-center hemodialysis continues to be the backbone of renal care delivery in Saudi Arabia, accounting for an estimated 85% of dialysis treatments. Services are provided through government-operated hospitals and emerging private sector clinics. However, peritoneal dialysis (PD) is gaining acceptance as a viable at-home alternative, thanks to its flexibility, improved quality of life for patients, and lower infrastructure requirements.

The Saudi Ministry of Health and regulatory authorities are promoting PD through training programs, patient education, and reimbursement incentives. Two major national hospitals in Riyadh and Jeddah introduced “home dialysis starter kits” in late 2024, aiming to increase patient awareness and trial rates. Analysts expect PD usage to rise from a current 15% to approximately 25% of dialysis cases by 2028.

Inquire Before Buying

Healthcare Reforms and Funding Mechanisms

Saudi Arabia’s Vision 2030 healthcare reforms are reshaping financing and delivery of dialysis services. The National Health Insurance Act is enabling insurance providers and private clinics to enter the hemodialysis space, raising standards and investment.

Under newly revised Saudi Health Insurance Plans, dialysis services—including in-patient, outpatient, and home-based treatments—are included with limited co-payments for patients, improving access. The government’s continued investments in medical infrastructure, combined with private sector licensing, are expanding regional clinic networks across secondary cities.

Furthermore, the King Salman Renal Program, initiated in 2023, is funding early CKD detection, community-based screening, and patient mobility solutions—helping detect earlier-stage disease and improve outcomes.

Technological Innovation and Facility Upgrades

The introduction of modern dialysis machines, real-time data integration, and patient-centric service models is elevating treatment quality. Key technological developments include:

• Advanced hemodialysis machines with smart blood-volume monitoring and electronic health record (EHR) integration
• Tele-nephrology platforms enabling remote consultations and treatment oversight
• Automated peritoneal dialysis systems and smartphone-based therapy controllers
• AI-enabled patient risk scoring to predict complications and reduce hospitalizations

Several Saudi health groups, in partnership with global suppliers like Fresenius and Baxter, are piloting wearable dialysis prototypes and remote assistance platforms in major cities. These early-stage trials aim to support better patient self-management and flexibility.

Expansion of Private Dialysis Networks

Saudi Arabia’s private dialysis sector is expanding rapidly. Companies such as Al Hammadi Healthcare, King Abdullah Medical City, and Alnahda Medical Group are investing in satellite dialysis clinics and regional centers.

These operators are partnering with public hospitals to deliver co-located clinics featuring enhanced services—nutrition counseling, psychosocial support, and transport logistics. Patients benefit from outpatient continuity of care and shorter waiting times. Expansion plans include 12 new dialysis facilities in Mecca, Medina, Dammam, and Abha, set to open by mid-2026.

Rural Challenges and Equity Initiatives

Rural and peripheral regions still face dialysis access limitations. Travel distances, workforce distribution, and infrastructure gaps have historically hindered treatment equity.

To address these, the Ministry of Health has introduced mobile dialysis units, patient tele-support services, and rotational nephrologist visits to regional centers.

Research and Collaboration

Saudi Arabia is establishing itself as a regional center for dialysis and nephrology research. Academic institutions—King Saud University and King Abdulaziz University—are collaborating with global partners on clinical trials for wearable artificial kidney prototypes and biocompatible dialysate studies.

Outlook: Patient-Centered and Data-Driven Dialysis Growth

Looking ahead, Saudi Arabia’s dialysis market is expected to evolve toward more personalized, integrated and patient-centered delivery. Key strategic priorities include:

• Expanding early CKD detection through public health screenings
• Advancing home-based dialysis adoption with education and subsidized kits
• Enhancing remote treatment oversight through tele-nephrology and patient portals
• Supporting domestic manufacturing of consumables under localization initiatives
• Strengthening insurance coverage for supportive therapies like anemia management and bone disease